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Abstract
Background Surgical treatments such as guided tissue regeneration (GTR) and access flap surgery are widely employed for the
treatment of intrabony defects. However, little is known regarding the postoperative expression of gingival crevicular fluid (GCF)
markers.
Objective The aim of this systematic review was to compare the expression of GCF markers following treatment of periodontal
intrabony defects with guided tissue regeneration or access surgery. The association of the markers’ expression with the clinical
outcome was also assessed.
Methods An electronic literature search was conducted inMEDLINE, EMBASE, OpenGrey, LILACS and Cochrane Library up
to December 2018 complemented by a manual search. Human, prospective clinical studies were identified. The changes from
baseline up to 30 days (early healing) and 3 months (late healing) were assessed.
Results A total of 164 publications were identified and reviewed for eligibility. Of these, 10 publications fulfilled the inclusion
criteria. The included studies evaluated 15 different GCF markers with a follow-up time between 21 and 360 days postopera-
tively. PDGF, VEGF and TIMP-1 changes were often investigated in the included studies; however, contrasting results were
reported. Two studies agreed that both GTR and OFD lead to similar OPG level changes. TGF-β1 is increased early postoper-
atively, irrespective of the surgical technique employed.
Conclusion There is limited evidence available on the expression of GCF markers after surgical interventions of intrabony
periodontal defects. However, OPG and TGF-β1 tend to increase early post-operatively, irrespective of the surgical technique
employed, irrespective of the surgical technique employed.
Clinical relevance More well-designed, powered studies with sampling periods reflecting the regenerative process are needed,
and future research should focus on employing standardised protocols for collecting, storing and analysing GCF markers.
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Introduction
Periodontitis is a chronic inflammatory disease caused by bac-
terial biofilm that leads to a progressive destruction of the
supporting apparatus of a tooth and eventually to tooth loss.
The prevalence of periodontitis, according to the 2009–2010
data from the National Health and Nutrition Examination
Survey (NHANES), reaches 46% in US adults [1].
As periodontal disease progresses, it results in bone loss
that can be horizontal or vertical or a combination of both. The
loss of supporting bone vertically results in the formation of
intrabony defects that progressively worsen and are associated
with an increased probability of tooth loss [2]. While non-
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surgical periodontal therapy is effective in improving the clin-
ical parameters, such as probing pocket depth (PPD) and clin-
ical attachment levels (CAL) [3], surgical approaches are
more effective—in particular for PPD of more than 6 mm
[4, 5]. Currently, intrabony defects are identified as sites
favourable for periodontal regeneration [6, 7] with the most
commonly used techniques being guided tissue regeneration
(GTR) and enamel matrix derivatives (EMD) presenting with
similar clinical outcomes which are superior to open flap de-
bridement (OFD) and osseous surgery (OS) [8–10].
However, irrespective of the regenerative modality employed
for the treatment of intrabony defects, little is known regarding
the processes and sequences involved in the periodontal regen-
eration and consequently, in the postoperative expression of an-
giogenesis, regeneration and inflammation markers in the gingi-
val crevicular fluid (GCF) that accompany these processes [11].
The expression of such markers postoperatively may define
whether the healing process moves towards a regenerative or a
reparative direction [11]. Understanding the cellular and biolog-
ical events in periodontal wound healing can possibly provide
useful information in identifying predictable regenerative treat-
ment for the periodontium.
The aim of this systematic review was to investigate the
healing patterns of intrabony defects after surgical interven-
tions (GTR, OS, OFD, EMD) by means of angiogenesis, re-
generation and inflammation markers detected in the GCF
before and early (≤ 30 days) or late (3 months) after the sur-
gical intervention. Furthermore, the association of the expres-
sion of the GCF markers with the clinical outcome was
investigated.
Materials and methods
Protocol and Registration
The present systematic review followed the PRISMA
(Preferred Reporting Items for Systematic Review and Meta-
Analyses) guidelines [12] (Supplemental Material 1) and was
registered with PROSPERO under the ID number
CRD42018115794.
PICO question
The PICO question (patient, intervention, comparison and
outcome) formulated was: “In patients with periodontal
intrabony defects, does the expression of GCF markers for
angiogenesis, regeneration and inflammation differ when
treated with GTR employing a membrane and/or bone graft
and/or biologics (e.g. EMD) (test group(s)) compared with
intrabony defects treated with access surgery [OFD or OS or
apically positioned flap (APF)] (control group) early (≤ 30
days) and late (3 months) after the surgical intervention?”
Eligibility criteria
Types of studies
Human, prospective clinical studies assessing the expression
of angiogenesis, regeneration and inflammationmarkers in the
GCF were considered. Only studies with at least ten patients
per group were included. No language restriction was set.
Population
Systemically healthy individuals with chronic periodontitis
(CP) with at least one tooth with PPD ≥ 5 mm, CAL and
evidence of radiographic bone loss or aggressive periodontitis
[13, 14] or periodontitis stages III or IV [15] and contributing
a minimum of 1 intrabony defect.
Intervention and comparison
Intrabony defects treated with GTR employing a mem-
brane and/or bone graft and/or with biologics (e.g.
Emdogain) (test group(s)) and intrabony defects treated
with access flap surgery (OFD or OS or APF) (control
group). No restriction related to the flap technique (min-
imally invasive or not) was applied to avoid omitting po-
tentially relevant data. Intrabony defects treated with ad-
junct growth factors e.g. EMD were included in the test
group(s).
Outcome measures
The primary outcome of this review was the change in the
expression of angiogenesis, regeneration and inflamma-
tion markers in the GCF during early healing (from base-
line up to 30 days) and during late healing (from baseline
to at least 3 months postoperatively). Secondary outcomes
considered were the association of the expression of GCF
markers (early and/or late healing) with the clinical out-
come, assessed with the use of surrogate measures such as
PPD and/or CAL.
Information sources and electronic search
An electronic search was conducted by two independent re-
viewers (VK and GC) in MEDLINE, EMBASE, Cochrane
Library, LILACS and OpenGrey for publications up to 10
December 2018. Combinations of controlled terms (MeSH
and EMTREE) and keywords were utilised:
(“infrabony” or “intrabony” or “infra-bony” or “intra-
bony” or “angular defect” or “periodontal defect”) and (“guid-
ed tissue regeneration” or “GTR” or “periodontal regenera-
tion” or “periodontal surgery” or “open flap debridement” or
“OFD” or “access surgery”) and (“gingival crevicular fluid”
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or “crevicular fluid” or “GCF” or “inflammatory marker” or
“marker” or “growth factor” or “inflammatory mediator” or
“biomarker”)
Additionally, a manual search of periodontology-related
journals including Journal of Dental Research, Journal of
Clinical Periodontology, Journal of Periodontal Research
and the Journal of Periodontology was performed from 2015
to 2018. The list of references in the publications included in
this review as well as the list of references in relevant reviews
were screened for potential additional publications fulfilling
the inclusion criteria.
Study selection
The search results were initially screened for relevancy by
means of title, keywords and abstract, independently and in
duplicate by two reviewers (VK, GC). Irrelevant records were
excluded at this stage. Any conflict was resolved with discus-
sion. At the second round of screening, the full text of the
publications remaining after the first round was assessed for
inclusion in this review against the eligibility criteria de-
scribed previously. The level of agreement between the two
reviewers was calculated using Kappa statistics.
Data collection process/data items
The characteristics of the included publications were extracted
by two reviewers (VK, GC). Among the details extracted were
study characteristics (authors, journal of publication, year,
country), number of patients, their demographics and risk fac-
tors (age, gender, smoking), diagnosis, number of intrabony
defects, history of non-surgical treatment of the sites and time
elapsed, characteristics of the included defects, surgical pro-
cedure employed (GTR, OFD), biomaterials used in the test
group(s), postoperative care protocol, exposure rate, follow-
up period, expression levels of the GCF markers, clinical out-
comes (PPD, CAL), details of the methodology employed for
the GCF sampling, storage, processing and detection of the
markers, information regarding the main study outcome and
power calculation of the study. When data from the included
studies were missing, the authors of the publication were
contacted through email.
Risk of bias assessment
The risk of bias of the included publications was assessed by
the two reviewers independently and in duplicate. For the RCTs
included, the quality of the selected publications was assessed
according to the Cochrane Collaboration’s tool for assessing
risk of bias [16]. The selected publications were assessed for
seven domains: sequence generation, allocation concealment,
blinding of the participants and personnel, blinding of the out-
come assessment, incomplete outcome data, free of selective
outcome reporting and other sources of bias. For each of the
individual domains, studies were classified as low, unclear or
high risk of bias. Observational studies were assessed using the
MINORS tool [17]. Studies were assessed in 12 items including
clarity of the aim, inclusion of consecutive patients, prospective
data collection, appropriateness of end points, unbiased assess-
ment of study end points, appropriateness of follow-up time,
inclusion of loss to follow-up rate, prospective calculation of
the study size, comparable control group, contemporary control
groups, baseline equivalence of groups on several factors and
adequate statistical analysis. Each study may receive 0–2 points
for each item and the total score ranges from 0 to 24 points.
Studies with fewer than 16 points are considered of low quality,
while high-quality studies need to have a score of greater than
or equal to 16.
Results
Study selection
The flowchart of the study selection and inclusion process is
shown in Fig. 1. The initial search identified 68 MEDLINE,
110 EMBASE, 59 Cochrane database and 1 LILACS titles,
with a total of 163 after duplicates’ removal. One additional
title was identified through hand search for a total of 164 titles.
Following the screening of titles and abstracts by the two
reviewers, 10 articles qualified for full text screening and all
10 met the inclusion criteria. The kappa value for inter-
reviewer agreement was 0.99 at first round and 1.00 at second
round.
Study characteristics
The characteristics of the included studies are presented in
Table 1. All 10 included articles were in English. The study
samples ranged from 12 [18] to 29 [19] patients. Seven of the
included studies were randomised controlled clinical trials
[18–24] and the remaining 3 were prospective cohort studies
[11, 25, 26].
The characteristics of the included intrabony defects ranged
from PD ≥ 5 mm [11, 19, 24–26] to PD ≥ 6 mm [18, 20–23]
and accompanying radiographic defect depth ≥ 3 mm [11, 18,
20, 21, 24], ≥ 4 mm [19, 23] or unspecified [22, 25, 26]. The
defects included were variations of 1-, 2-, 3-wall defects [18,
24], only 2- or 3-wall defects [20, 21] or non-specified in the
majority of the investigations [11, 19, 22, 23, 25, 26].
The types of procedures included in the test group were
GTR [11, 20–22, 24–26] GTR with EMD [18, 23], and min-
imally invasive surgical technique (MIST) with EMD [19].
Non-resorbable membranes that were removed 6 weeks post-
operatively were utilised in 3 studies [11, 25, 26].
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Five of the included studies utilised Periopaper for the sam-
pling of the GCF [11, 18, 19, 22, 23], 3 studies utilised pre-cut
chromatography strips (Whatman 3MM) [24–26] and 2 studies
utilised micropipettes [20, 21]. The GCF sampling time present-
ed significant variation across studies, ranging from 30 s [11, 19,
22] to 1min [23] and 2min [24–26], while some studies allowed
the insertion of the strip or the pipette until 5 μl were collected
[20, 21] with one study not reporting on the sampling time [18].
Regarding the storage of the samples, great variation was also
observed: 2 studies stored their GCF samples at − 80 °C [18, 23],
1 study at − 76 °C [21], 4 studies at − 70 °C [22, 24–26], 1 study
at − 26 °C [20] and 2 studies at − 20 °C [11, 19]. Eight of the
included studies analysed the GCF samples using enzyme-linked
immunosorbent assay (ELISA) [11, 18–21, 23, 25, 26], 1 study
used reverse-phase high-performance liquid chromatography
with fluorimetric detection [22] and 1 study usedmultiplex beads
assay [24]. Several GCFmarkers were investigated in the includ-
ed studies. For facilitating the reader, the GCF markers were
categorised under factors related with the healing of the epitheli-
um, the connective tissue, the bone and others, even if some
overlap might exist (Table 2).
The follow-up of the expression of GCFmarkers ranged from
21days [11] to 360 days [24], while the follow-up of the clinical
parameters after treatment ranged from 90 [23] to 360 days [24].
However, there was rarely coincidence of the sampling times for
the GCF markers with the clinical assessments postoperatively.
Finally, only 2 studies [21, 24] reported the postoperative
occurrence of exposures. Gamal et al excluded the exposed
sites from the study [21], while Rakmanee et al reported that
13 out of the 18 sites presented exposure of the membrane that
was treated either with removal of the membrane (2 sites,
classified as major exposure with size > 4 mm) or with ad-
ministration of antibiotics (2 sites, classified as minor) [24].
Synthesis of results
The results and conclusions of the individual studies included
are presented in Table 2. Due to the significant heterogeneity
of the included studies, in relation to the methodology
employed, a meta-analysis was not performed.
GTR
Regarding GTR, 7 studies reported on the expression of GCF
markers postoperatively [11, 20–22, 24–26]. Both Gamal, 2011
[20] and Gamal 2016 [21] employed the same GCF sampling
method using a micropipette inserted at 2mm depth in the sulcus
and filled with 5μL of GCF. The samples were subsequently
stored at -76C and analysed with ELISA. The concentrations
of platelet-derived growth factor-BB (PDGF-BB) peaked during
the early stages of healing (< 14 days) and decreased to baseline
values by 30 days. Similarly, Rakmanee et al employing a dif-
ferent methodology, using pre-cut chromatography strips at the
entrance of the gingival crevice for 2 min and stored at − 70C,
found again increased PDGF-AB amounts 7 days postoperative-
ly that decreased to baseline levels after 42 days [24].
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Furthermore, Rakmanee et al found similar PDGF-AB levels
both after GTR and after OFD that were accompanied by a
similar clinical response. However, the sites subjected to GTR
were associated with high rates of exposure (13/18) that may
have significantly affected the regenerative process and thus the
clinical response observed.
Furthermore, Rakmanee et al reported that GCF osteopro-
tegerin (OPG) amounts significantly increased 2–3 days post-
operatively and subsequently declined [24]. No significant
differences were noted between sites treated with GTR and
sites treated with OFD. Pellegrini et al. using Periopaper
inserted in the gingival crevice for 30 s found OPG levels to
decrease following GTR and OFD; however, no comparison
by treatment was reported for the change of the marker [11].
The expression levels of vascular endothelial growth factor
(VEGF) were investigated by Rakmanee et al. [24] and Gamal
et al. [21]. The former did not detect any significant difference in
the change of VEGFGCF levels between sites treated with GTR
and sites treated with access surgery using pre-cut chromatogra-
phy strips [24]. However, the study by Gamal and co-workers,
which usedmicropipettes, found that VEGF concentrationsmea-
sured statistically significant higher concentrations in defects
treated with OFD and GTR using a perforated membrane during
the early postoperative period (days 1, 3 and 7) compared to
defects treated using the occlusive membrane [21].
Kuru et al. 2004, using pre-cut chromatography strips at the
entrance of the gingival crevice for 2 min, found increased
transforming growth factor βi (TGF-β1 levels 2 weeks post-
operatively, that however were not statistically significant and
declined to below baseline levels by 4 weeks [26]. The change
in the TGF-β1 levels was similar both after GTR and after
OFD and accompanied a similar clinical response 6 months
postoperatively.
EMD
Regarding EMD, 3 studies reported on the expression of GCF
markers [18, 19, 23]. Ribeiro et al., using Periopaper in the
gingival crevice until resistance was felt and for 30 s, reported
that TGF-β1 levels in sites treated with MIST and EMD sig-
nificantly increased by 15 days postoperatively and the levels
decreased after 3 months [19]. Furthermore, the changes for
TGF-β1 levels were similar for sites treated with MIST and
MIST with EMD and accompanied a similar clinical and ra-
diographic response for both treatments. In contrast, Agrali
et al. using Periopaper, inserted in the gingival crevice for
unspecified amount of time, reported significantly higher
TGF-β1 levels for EMD-treated defects compared with
OFD-treated defects 7 and 14 days postoperatively [18]. In
the same line, the authors concluded that defects treated with
EMD presented a superior clinical and radiographic improve-
ment compared with defects treated with OFD. It is however
worth noting that the majority of the defects treated with EMD
Table 2 Summary of the conclusions of the included studies. (CAL
clinical attachment level, PD probing depth, PPD probing pocket
depth, OFD open flap debridement, MIST minimally invasive surgical
treatment, GTR guided tissue regeneration, vs versus, EGF epithelial
growth factor, KGF keratinocyte growth factor, TGF- βG transforming
growth factor β1, PDGF platelet-derived growth factor, VEGF vascular
endothelial growth factor, FGF fibroblast growth factor, MMP-1 matrix
metalloproteinase-1, MMP-8 matrix metalloproteinase-8, TIMP-1
metallopeptidase inhibitor-1, Ang-1 angiopoiet in-1, OPG
osteoprotegerin, OCN osteocalcin, BMP-2 bone morphogenetic protein-
2, BMP-7 bone morphogenetic protein-7, PAF platelet activating factor,
sICAM-1 soluble intercellular adhesion molecule-1, sLFA-3 lymphocyte
function-associated antigen-3)
FACTORS RELATED WITH THE HEALING OF EPITHELIUM
GCF marker Investigato
r, Year 
Is periodontal 
surgery leading to 
significant changes 
in the expression of 
GCF markers?
Is there any 
significant difference 
in the expression of 
GCF markers for 
intrabony defects 
treated with GTR vs 
OFD?
Is the study 
powered for 
GCF 
markers, for 
clinical 
outcomes or 
both?
Is there any 
significant difference 
in the clinical 
response for 
intrabony defects 
treated with GTR vs 
OFD? 
Is the expression of GCF 
markers directly associated 
with clinically significant 
changes following treatment?
E-cadherin
Pellegrini 
et al 2017 
No significant change 
observed for E-
cadherin for any group
Not reported No power 
calculation 
reported
Higher percentage of 
‘better responders’ in 
GTR vs OFD.
No conclusion can be drawn 
for the association of E-
cadherin with the clinical 
outcome
EGF
Pellegrini 
et al 2017 
EGF levels 
significantly increased
post-op in GTR 
Not reported No power 
calculation 
reported
Higher percentage of 
‘better responders’ in 
GTR vs OFD.
No conclusion can be drawn 
for the association of EGF with 
the clinical outcome
KGF
Rakmanee 
et al 2018
KGF amounts 
increased (non-
significantly) at 7 days
and decreased to 
baseline levels for 
GTR and access 
surgery
No significant 
differences in KGF 
amount between GTR 
and access surgery.
Powered for 
clinical 
outcomes
No significant 
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and radiographic 
defect resolution for 
GTR or access surgery 
The similar expression patterns 
of KGF accompanied a similar 
clinical response with GTR 
and access surgery
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GCF marker Investigato
r, Year  
Is periodontal surgery 
leading to significant 
changes in the 
expression of GCF 
markers? 
Is there any significant 
difference in the 
expression of GCF 
markers for intrabony 
defects treated with 
GTR vs OFD? 
Is the study 
powered for 
GCF 
markers, for 
clinical 
outcomes or 
both? 
Is there any 
significant difference 
in the clinical response 
for intrabony defects 
treated with GTR vs 
OFD?  
Is the expression of 
GCF markers directly 
associated with 
clinically significant 
changes following 
treatment? 
TGF-β1 
Agrali et al 
2016   
GCF volume and TGF-
β1 levels increased at 7 
days post-op and then 
decreased to below 
baseline levels (by 90 
days) for both EMD and 
EMD + autograft 
TGF-β1 could not be 
detected in 41% of OFD, 
26% of EMD and 6% of 
EMD + autograft during 
the follow up (0 to 180 
days). EMD and 
EMD+autograft showed 
significantly higher TGF-
β1 concentrations at 7 
days and TGF-β1 
amounts at 14 and 180 
days vs OFD. 
Powered for 
clinical 
outcomes 
Clinical and 
radiographic 
improvements noted for 
all groups. EMD and 
EMD + autograft 
presented statistical 
significantly higher 
CAL gain and 
radiographic defect fill 
vs OFD. No significant 
difference for EMD and 
EMD + autograft.  
The trend for increased 
TGF-β1 expression 
observed in EMD and 
EMD + autograft 
correlates with a 
superior clinical 
response, compared to 
OFD.  
Ribeiro et al 
2011 
 
TGF-β1 levels 
significantly increased 
after 15 days and reduced 
to baseline levels after 3 
months for MIST and 
MIST + EMD.  
Similar changes in TGF-
β1 levels were observed 
for both groups, MIST 
and MIST + EMD 
Powered for 
clinical 
outcomes 
Similar clinical and 
radiographic 
improvements were 
noted for both groups  
Similar expression 
patterns in TGF-β1 
accompanied a similar 
clinical response with 
MIST and MIST + 
EMD 
Kuru et al 
2004  
TGF-β1 levels increased 
two-fold 2 weeks post-op 
(not statistically 
significant), declined to 
levels lower than 
baseline after 4 weeks 
and remained stable until 
26 weeks for GTR and 
conventional flap 
TGF-β1 levels were 
similarly increased for 
GTR and conventional 
flap treated sites  
Power 
calculation 
not reported  
No statistically 
significant differences 
between GTR and 
conventional flap noted 
for clinical parameters 
6 months post-op. 
Similar expression 
patterns in TGF-β1 
accompanied a similar 
clinical response with 
GTR and conventional 
flap 
FACTORS RELATED WITH THE HEALING OF CONNECTIVE TISSUE
Pellegrini et 
al 2017
TGF-β1 levels were 
decreased compared to 
baseline following 
regeneration surgery 
A downward trend was 
detected only after GTR 
but not after OFD (non-
significant differences 
between groups) 
No power 
calculation 
performed
A higher percentage of 
‘better responders ‘in 
terms of PD and CAL 
was found in GTR vs 
OFD. 
No conclusion can be 
drawn for the 
association of TGF-β1 
with the clinical 
outcome
PDGF
Gamal et al 
2011 
PDGF-BB concentrations 
peaked during the early 
post-op days (days 2 and 
3) and decreased at 7,14, 
and 30 days in GTR and 
OFD
No significant difference 
was found in PDGF-BB 
concentrations between
GTR with periosteum 
membrane and OFD 
sites.
Power 
calculation 
not reported
GTR led to statistically 
significantly higher 
PPD reduction, CAL 
gain and intrabony 
component reduction vs
OFD.
No conclusion can be 
drawn for the 
association of PDGF 
levels with the clinical 
outcome
Gamal et al 
2016 
PDGF-BB concentrations 
at GTR with perforated 
membranes and OFD 
sites peaked during the 
early stages of healing 
(1-14 days) and then 
decreased at 21 and 30 
days
PDGF-BB levels at GTR 
with perforated 
membranes and OFD 
sites showed statistically 
significant higher levels 
than GTR with occlusive 
membrane at 1, 3, 7, 14 
days. PDGF-BB levels 
decreased gradually at 
days 21 and 30 in all 
groups with no 
significant differences.
Powered for 
GCF markers 
and clinical 
outcomes
GTR with perforated 
membrane showed a 
statistically significant 
improvement in PPD, 
CAL and intrabony 
defect vs GTR with 
occlusive membrane 
and OFD. 
GTR with occlusive 
membrane-treated 
resulted in significant 
PPD reduction, CAL 
gain and reduction of 
the intrabony defect vs 
OFD.
No conclusion can be 
drawn for the 
association of PDGF 
levels with the clinical 
outcome
Rakmanee 
et al 2018
PDGF-AB amount 
increased early post-op
(7 days) and decreased to 
baseline levels after 42 
days for GTR and access 
surgery.
Similar changes for 
PDGF-AB were 
observed for GTR and 
access surgery.
Powered for 
clinical 
outcomes
No significant 
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and radiographic defect 
resolution noted for 
GTR or access surgery. 
Similar expression for 
PDGF-AB 
accompanied a similar 
clinical response after
GTR and access 
surgery
VEGF Pellegrini et VEGF levels increased 3 Not reported No power Higher percentage of No conclusion can be 
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al 2017 weeks following GTR calculation 
performed
‘better responders ‘was 
found in GTR vs OFD.
drawn for the 
association of VEGF 
levels with the clinical 
outcome
Gamal et al 
2016
VEGF concentrations 
peaked during the early 
post-op days (days 1-7) 
and decreased at 14, 21 
and 30 days.
VEGF concentrations 
were significantly higher 
for OFD and GTR with 
perforated membrane 
during the early post-op
days (days 1, 3 and 7) vs 
GTR with occlusive 
membrane.
Powered for 
GCF markers 
and clinical 
outcomes
GTR with perforated 
membrane showed a 
statistically significant 
improvement in PPD, 
CAL and intrabony 
defect vs GTR with
occlusive membrane 
and OFD. 
GTR with occlusive 
membrane showed  a 
significant PPD 
reduction, CAL gain
and intrabony defect
reduction vs OFD
No conclusion can be 
drawn for the 
association of VEGF 
levels with the clinical 
outcome
Rakmanee 
et al 2018
In GTR and access 
surgery, the VEGF 
amount doubled early 
post-op (3-5 days) and 
decreased to baseline 
levels after 28 days. 
No significant difference 
was detected in the 
change of VEGF for 
GTR and access surgery
Powered for 
clinical 
outcomes
No significant 
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and defect resolution 
noted for GTR or 
access surgery. The 
total availability of 
VEGF at 30 days 
correlated with the 
clinical changes
Similar expression 
patterns in the levels of 
VEGF accompanied a 
similar clinical response 
with GTR and access 
surgery
FGF
Pellegrini et 
al 2017 
No significant change 
was observed for FGF-2 
levels after OFD or GTR
Not reported No power 
calculation 
performed
Higher percentage of 
‘better responders ‘was 
found for GTR vs OFD.
No conclusion can be 
drawn for the 
association of FGF with 
the clinical outcome
Rakmanee 3-5 days post- No significant Powered for No significant Similar expression 
et al 2018 operatively, bFGF 
amounts increased (not 
statistically 
significantly), peaked at 
7 days and decreased to 
baseline levels for GTR 
and access surgery.
differences in the bFGF 
amount were noted 
between GTR and access 
surgery.
clinical 
outcomes
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and radiographic defect 
resolution were noted 
for GTR or access 
surgery. 
patterns in the bFGF 
levels accompanied a 
similar clinical response 
with GTR and access 
surgery
MMP-1
Okuda et al 
2001
Intragroup analysis 
showed a significant 
decrease for MMP-1 
from 2 to 4 weeks after 
surgery. 
No significant changes 
noted for MMP-1 levels 
in the placebo group. 
Intergroup analysis 
showed significantly 
lower MMP-1 levels at 2, 
4 and 12 weeks in EMD 
vs placebo.
Power 
calculation 
not reported
Intragroup differences 
between baseline and 
12 weeks showed a 
significant decrease in 
PPD and CAL. 
No significant 
intergroup differences 
noted.
Despite the different 
expression patterns in 
the levels of MMP-1, a 
similar clinical response 
with EMD and control 
was noted.
Pellegrini et 
al 2017 
MMP-1 levels increased 
in ‘worse responders’
and remained 
substantially unchanged 
in ‘better
responders’.
Not reported No power 
calculation 
performed
Higher percentage of 
‘better responders ‘was 
found in GTR vs OFD.
No conclusion can be 
drawn for the 
association of MMP-1 
levels with the clinical 
outcome
MMP-8
Okuda et al 
2001
Intragroup analysis 
showed a significant
increase in MMP-8 for 
EMD and control
significantly increased
at 2 weeks. There was a 
decrease in MMP-8 
levels for EMD between 
2 and 4 weeks and for 
both groups between 2
Intergroup analysis 
demonstrated 
significantly lower 
MMP-8 levels for EMD 
vs placebo at 4 and 12 
weeks
Power 
calculation 
not reported
Intragroup differences 
between baseline and 
12 weeks showed a 
significant decrease in 
PPD and CAL. 
No significant 
intergroup differences 
were noted.
Despite the different 
expression patterns in 
MMP-8 levels, a similar 
clinical response with 
EMD and control was 
noted.
TIMP-1
Okuda et al 
2001
Both EMD and placebo, 
presented a significant 
increase in TIMP-1 
Intergroup analysis 
demonstrated 
significantly lower mean 
Power 
calculation 
not reported
Intragroup differences 
between baseline and 
12 weeks showed a 
Despite the different 
expression patterns in 
the levels of TIMP-1, a 
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between baseline and 2 
weeks. 
Significant decreases in 
TIMP-1 levels at 4 and 
12 weeks when 
compared to 2 weeks 
were noted for both 
groups. 
levels of TIMP-1 at 4 
weeks for EMD
vs placebo 
significant decrease in 
PPD and CAL. 
No significant 
intergroup differences 
were noted. 
similar clinical response 
with EMD and control 
was noted.
Pellegrini et 
al 2017 
Following GTR, a trend 
for increased TIMP-1 
levels was observed
Not reported No power 
calculation 
performed
Higher percentage of 
‘better responders ‘was 
found for GTR vs OFD.
No conclusion can be 
drawn for the 
association of TIMP-1 
levels with the clinical 
Rakmanee 
et al 2018
3-5 days post-op, TIMP-
1 amounts increased 
significantly for GTR, 
access flap or control 
sites. At 7 days, TIMP-1 
amount decreased to 
baseline levels for GTR, 
while access surgery sites 
presented reduced levels 
after 14 days.
No significant 
differences in TIMP-1 
amount were noted for 
GTR and access surgery.
Powered for 
clinical 
outcomes
No significant 
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and radiographic defect 
resolution were noted 
for GTR or access 
surgery. 
Similar expression 
patterns in levels of 
TIMP-1 accompanied a 
similar clinical response 
with GTR and access 
surgery
Ang-1
Rakmanee 
et al 2018
3-5 days post-op, Ang-1 
amounts increased 
significantly, peaked at 7 
days and decreased to 
baseline levels for GTR. 
For access flap, Ang-1 
amount increased by 7 
days and declined to 
baseline levels.
No significant 
differences in Ang-1 
amount between GTR 
and access surgery.
Powered for 
clinical 
outcomes
No significant 
differences for CAL 
gain, PPD reduction, 
radiographic bone fill 
and radiographic defect 
resolution were noted 
Similar expression 
patterns in the levels of 
Ang-1 accompanied a 
similar clinical response 
with GTR and access 
surgery
between GTR and
access surgery.  
FACTORS RELATED WITH THE HEALING OF BONE 
GCF marker Investigato
r, Year 
Is periodontal surgery 
leading to significant 
changes in the 
expression of GCF 
markers?
Is there any 
significant difference 
in the expression of 
GCF markers for 
intrabony defects 
treated with GTR vs 
OFD?
Is the study 
powered for 
GCF 
markers, for 
clinical 
outcomes or 
both?
Is there any significant 
difference in the clinical 
response for intrabony 
defects treated with GTR 
vs OFD? 
Is the expression of GCF 
markers directly 
associated with clinically 
significant changes 
following treatment?
OPG
Ribeiro et al 
2011
Significant increases for
OPG noted after 15 
days, but no differences 
observed after 3 months
Similar changes in OPG 
levels observed for both 
groups, MIST and 
MIST + EMD
Powered for 
clinical 
outcomes
Similar clinical and 
radiographic 
improvements were noted 
for both groups
Similar expression patterns 
in the levels of OPG 
accompanied a similar 
clinical response with 
MIST and MIST + EMD
Rakmanee 
et al 2018
OPG amount 
significantly increased 
(2-fold) 3-5 days post-
op for GTR and 
declined. A non-
significant increase was 
noted for access 
surgery. 
Similar OPG levels 
were observed for both 
groups, GTR and access
surgery, that were 
significantly higher 
than healthy control 
sites 
Powered for 
clinical 
outcomes
No significant differences 
for CAL gain, PPD 
reduction, radiographic 
bone fill and radiographic 
defect resolution were 
noted for GTR and access 
surgery. 
Similar expression patterns 
in the levels of OPG 
accompanied a similar 
clinical response with 
GTR and access surgery
Pellegrini et 
al 2017 
OPG levels were 
decreased after GTR
and OFD.
Not reported No power 
calculation 
performed
Higher percentage of 
‘better responders ‘was 
found in GTR vs OFD.
No conclusion can be 
drawn for the association 
of OPG levels with the 
clinical outcome.
OCN
Ribeiro et al 
2011
No significant changes 
were noted for OCN 
levels up to 3 months 
post-op
No significant changes 
for OCN levels were 
observed for any group.
Powered for 
clinical 
outcomes
Similar clinical and 
radiographic 
improvements were noted 
for both groups
No conclusion can be 
drawn for the association 
of OCN levels with the 
clinical outcome.
BMP-2
Rakmanee 
et al 2018
3-5 days post-op, BMP-
2 amounts increased 
(significantly for GTR), 
No significant 
differences in the BMP-
2 amount between GTR 
Powered for 
clinical 
outcomes
No significant differences 
for CAL gain, PPD 
reduction, radiographic 
Similar expression patterns 
in the levels of BMP-2 
accompanied a similar 
peaked at 7 days and 
decreased to baseline 
levels for GTR and 
access surgery
and access surgery were 
noted.
bone fill and radiographic 
defect resolution were 
noted between defects 
treated with GTR or access 
surgery. 
clinical response with 
GTR and access surgery
BMP-7
Pellegrini et 
al 2017 
BMP-7 levels tended to 
increase for ‘better
responders’ (by means 
of PD and CAL) and to 
decrease for ‘worse 
responders’.
Not reported No power 
calculation 
performed
Higher percentage of 
‘better responders‘ was 
found for GTR vs OFD.
No conclusion can be 
drawn for the association 
of BMP-7 levels with the 
clinical outcome
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were localised at anterior teeth, compared with the majority of
the sites treated with OFD that were localised at molar teeth.
Okuda et al . described an increase for matrix
metalloproteinase-8 (MMP-8) and metallopeptidase inhibitor
1 (TIMP-1) GCF levels 2 weeks postoperatively for defects
treated with EMD and OFD that thereafter declined, more
dramatically for EMD-treated defects [23]. MMP-1 levels sig-
nificantly decreased from 2 to 4 weeks postoperatively for
defects treated with EMD [23].
Ribeiro et al. using Periopaper in the gingival crevice for 30 s
concluded that OPG levels increase 15 days postoperatively and
similar changes are noted after both MISTand MISTwith EMD
[19]. Interestingly, Rakmanee et al. concluded that the OPG
amount significantly increased 2–3 days postoperatively and sub-
sequently declined with no significant differences between sites
treated with GTR and OFD [24]. Consequently, similar changes
were noted for the OPG levels after MIST and MISTwith EMD
or after GTR and access flap. Furthermore, both studies reported
similar clinical and radiographic improvements for both treat-
ment groups [19, 24]; thus, the similar expression patterns in
the levels of expression of OPG accompanied a similar clinical
response, irrespective of the surgical technique employed.
GTR and EMD
Regarding the combination of GTR and EMD, Agrali et al.
reported on the levels of TGF-β1. The combination-treated
defects, similarly distributed to anterior and posterior teeth, pre-
sented similar changes in the TGF-β1 levels as the EMD-
treated defects in the first 2 postoperative weeks [18]. The sim-
ilar changes of TGF-β1 levels accompanied a similar clinical
response for EMD and EMD with GTR, that was superior to
OFD. However, as discussed previously the majority of the
defects treated with OFD were localised in posterior teeth.
OFD
Finally, regarding OFD alone, there is agreement between two
investigations that an increase in TGF-β1 levels is initially ob-
served, accompanied by a return to baseline levels by 14 days
OTHER GCF FACTORS
GCF marker Investigato
r, Year 
Is periodontal surgery 
leading to significant 
changes in the 
expression of GCF 
markers?
Is there any 
significant difference 
in the expression of 
GCF markers for 
intrabony defects 
Is the study 
powered for 
GCF 
markers, for 
clinical 
Is there any significant 
difference in the 
clinical response for 
intrabony defects 
treated with GTR vs 
Is the expression of 
GCF markers directly 
associated with 
clinically significant 
changes following 
treated with GTR vs 
OFD?
outcomes or 
both?
OFD? treatment?
PAF
Keles et al 
2006
Significant decreases in 
PAF levels for GTR 
and flap surgery were 
noted at 6, 12 and 24 
weeks post-operatively 
compared to pre-
surgery 
No significant 
differences in PAF 
levels
between the study 
groups pre-operatively
and at 6, 12 and 24 
weeks postoperatively 
were noted
Power 
calculation 
not reported
Both treatment 
modalities significantly 
reduced the PPD and 
improved the CAL. No 
significant differences 
were observed between 
the groups.
Similar expression 
patterns in the levels of 
expression of PAF 
accompanied a similar 
clinical response with 
GTR and flap surgery
sICAM-1
Kuru et al 
2005
For sites treated with 
GTR and conventional 
flap, the total amount of 
sICAM-1 increased 
during the initial 2-4 
weeks (non-
significantly) and then 
reduced at a lower level 
than baseline up to 12 
weeks
No significant 
differences in sICAM-
1 amount between the 
groups were noted
Power 
calculation 
not reported
Not reported No conclusion can be 
drawn for the 
association of the 
sICAM-1 levels with 
the clinical outcome.
sLFA-3
Kuru et al 
2005
For sites treated with 
GTR and conventional 
flap, the total amount of 
sLFA-3 significantly 
increased at 2 weeks 
and thereby returned to 
baseline levels 
No significant 
differences in
sLFA-3 amount
between the groups
were noted
Power 
calculation 
not reported
Not reported No conclusion can be 
drawn for the 
association of the 
sLFA-3 levels with the 
clinical outcome.
No significant difference between Significant difference between Data is Inconclusive 
groups groups 
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[18, 26]. For PDGF, conflicting results are presented; Gamal and
co-workers reported an initial increase and a decrease by 7 days
postoperatively to below baseline levels [20]. In contrary, another
investigation from the same group reported a decrease for the
PDGF levels that continued until 30 days postoperatively [21].
Rakmanee et al. noted an increase in the PDGF amount after
OFD that continued until 3 months postoperatively [24].
For the remaining markers and for more detail regarding
the expression of the investigated GCF markers after the sur-
gical treatments, the reader is referred to the detailed Table 2.
Risk of bias assessment
The risk of bias assessment is presented in Fig. 2 and Table 3.
Seven of the included studies (RCTs) were assessed using the
Cochrane Collaboration tool [18–24]. Four of the seven stud-
ies were of low risk of bias in all but one domain [19, 20, 22,
23], two were of low risk of bias in five domains [21, 24] and
one [18] was of high risk of bias. The remaining three studies
[11, 25, 26] were prospective cohort studies and were
assessed using the MINORS tool. These studies were rated
with 16 to 18, indicating high quality of the included
studies.
Discussion
This systematic review identified 15 GCF markers expressed
after surgical treatment of intrabony defects (GTR, OS, OFD).
For 7 of those, most of which are related with the healing of
connective tissue, TGF-β1, PDGF, VEGF, FGF, MMP-1,
TIMP-1 and OPG, data was available from more than one
investigation. While for the majority of factors a definitive
conclusion cannot be reached, robust suggestions can be
drawn regarding the OPG levels in regenerative surgeries. In
two investigations, employing different GCF sampling and
storing techniques, the OPG levels after MIST or MIST with
EMD and after GTR or access flap similarly increased within
the two postoperative weeks and thereafter declined [19, 24].
Furthermore, both studies reported similar clinical and radio-
graphic improvements; thus, the similar expression patterns of
OPG likely accompanied a similar clinical response. OPG acts
as a soluble decoy receptor, binding to the receptor activator of
nuclear factor-kappa B (RANKL) and inhibiting the
osteoclastogenic action [27]. Therefore, OPG has been iden-
tified as a critical factor in bone formation and the regulation
of bone resorption.
The finding of this review however comes in contrast with a
human polymerase chain reaction (PCR) study assessing the
Fig. 2 Risk of bias assessment of
RCTs using the Cochrane
Collaboration tool
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gene modulation 21 days following treatment of intrabony de-
fects with either GTR with an expanded polytetrafluorethylene
(ePTFE) membrane or flap surgery [28]. Among others, OPG
mRNA levels were significantly higher in GTR sites, compared
with access flap sites. Furthermore, in an investigation of the
gene expression profile of cells derived from GTR subjected
defects (regenerating-tissue derived cells–RTCs), a differential
and highlighted expression of the gene encoding OPG
(TNFRSF11B) was found compared with matched periodontal
ligament mesenchymal cells (PLCs) [29]. These contrasting re-
sults may be due to the high rate of exposures (13/18 GTR sites)
in the study by Rakmanee et al. that may have significantly
affected the regenerative process and thus the OPG expression
[24]. In addition, the Ribeiro et al. investigation, as most of the
included studies, was not powered for GCF and could therefore
lack statistical power to detect differences in the expression levels
between treatments [19].
Interestingly, Okuda et al. found that the use of EMD in
intrabony defects resulted in an early postoperative increase
for MMP-8 and TIMP-1, followed by an accelerated return to
baseline levels, when compared to OFD [23]. This highlighted
reduction may associate with an EMD-induced accelerated
pattern of wound healing and resolution of inflammationmov-
ing towards regeneration rather than repair.
With respect to PDGF, three isoforms exist (AA, AB, BB).
Two studies included in this review [20, 24] demonstrated that
GTR and access flap lead to similar changes: an initial in-
crease of PDGF-BB [20] and PDGF-AB [24] during the early
healing period (up to 7 days), accompanied by a decrease to
baseline levels. Two PDGF receptors exist, the PDGF-Rα and
the PDGF-Rβ who binds PDGF-AB with low and PDGF-BB
with high affinity [30]. In contrast with the included in this
review studies, a significant upregulation of PDGF-Rβ in
regenerating periodontal tissues has been observed [31] sug-
gesting that the ligands are involved in the early cascade of
events involved in regeneration.
Furthermore, in the only study powered for GCF markers
[21], perforated PTFE membranes were shown to result in sig-
nificantly higher VEGF during the early healing period (1, 3 and
7 days) when compared to occlusive membranes. In an animal
model of GTR using porcine extracellular matrix (ECM), mem-
brane cells recruited early postoperatively into the membrane
compartment result in highlighted expression of, among other
factors, VEGF at the RNA level. The VEGF expression was
significantly highlighted 3 days postoperatively and thereby de-
creased by 28 days [32]. This VEGF upregulation, along with
other regenerativemolecules, early postoperatively in themRNA
and the protein level, may suggest that the membrane itself acts
as a bioactive compartment guiding the regenerative process and
not solely as an active barrier.
TGF-β1 is a connective tissue cell signalling protein that
plays a critical role in several stages of wound healing, as it
promotes the mitogenic activity of gingival and periodontal
ligament cells and the upregulation of extracellular matrix com-
ponents [33, 34]. With regards to TGF-β1, the existing litera-
ture is conflicting. The studies included in this review studies
suggest that the clinical and radiographic outcome may be re-
lated to the TGF-β1 level changes [19, 26]. Ribeiro et al and
Kuru et al showed that GTR or OFD and MIST or EMD treat-
ments exhibited similar TGF- β1 increase early post-operative-
ly, as well as similar clinical and radiographic improvements
[19, 26]. However, the significant clinical and radiographic im-
provement following EMD in Agrali’s study was associated
with a significant TGF- β1 increase for EMD at anterior teeth,
Table 3 Risk of bias assessment
of observational studies using the
MINORS tool. Studies were
assessed in 12 items and can
receive 0–2 points for each for a
total score ranging from 0 to 24
points. Studies with fewer than 16
points are considered of low
quality while high quality studies
need to have a score of greater
than or equal to 16
Minors tool Kuru L, J
Periodontol. 2005
Kuru L, J Clin
Periodontol. 2004
Pellegrini, J Periodont
Res 2017
A clearly stated aim 2 2 2
Inclusion of consecutive patients 0 0 0
Prospective collection of data 2 2 2
End points appropriate to the
aim of the study
2 2 2
Unbiased assessment of the
study end point
0 0 0
Follow-up period appropriate to the
aim of the study
2 2 2
Loss to follow-up < 5% 2 2 1
Prospective calculation of
the study size
0 0 0
An adequate control group 2 2 2
Contemporary groups 2 2 2
Baseline equivalence of groups 0 2 1
Adequate statistical analyses 2 2 2
Total 16 18 16
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in contrast with OFD at mainly posterior teeth [18].When OFD
was employed alone for the treatment of intrabony defects, two
investigations agreed that an increase in TGF-β1 levels is ini-
tially observed, accompanied by a return to baseline levels by
14 days [18, 26]. In the same line, in an immunocytochemistry
investigation in biopsies, a highlighted increase was noted for
TGF-β1 receptor in regenerating periodontal tissues (6 weeks),
while the receptor was almost undetectable in healthy tissues
[31]. The highlighted receptor presence in regenerating tissues
may suggest that the corresponding TGF-β1 plays a pivotal
role in the early healing.
As it became evident, an important limitation was that only
one of the ten included studies [21] was powered to detect sig-
nificant differences in the GCF markers, whereas the remaining
nine studies were either powered for the clinical outcomes or did
not report any power calculation. Furthermore, inclusion of
intrabony defects with varying number of defect walls does not
allow for meaningful conclusions as regeneration is more likely
to occur in 3-walled defects and to be accompanied by a different
array of GCF markers compared to a 1-wall defect. In addition,
reportedly, a large variation across investigationswas observed in
the methodology employed for the GCF sampling, storage and
detection. These variations would introduce confounders if a
meta-analysis was attempted. For example, the sampling
methods (Periopaper, micropipette), the duration of collection
(30 s, 2 min, until a specific volume is collected), the depth of
strip insertion (entrance of the pocket or full depth), the storage
(temperature) or the preparation of the samples (processing indi-
vidual or pooled samples) introduce variations that would affect
the conclusions drawn and their generalisability. Furthermore, it
becomes imperative that more well-designed, powered studies
with sampling periods reflecting the regenerative process are
needed. Future investigations should employ standardised proto-
cols for GCF sampling, processing and storage.
In conclusion:
There is limited evidence available on the expression of
markers of angiogenesis, regeneration and inflammation in
the GCF in the early and late healing after surgical interven-
tions of intrabony periodontal defects
OPG is increased early postoperatively, irrespective of the
surgical technique employed
A trend is noted for TGF-β1 increase early postoperatively,
irrespective of the surgical technique employed. A highlighted
increase is noted after use of EMD at anterior teeth that may
relate with an improved clinical outcome.
More well-designed, powered studies with sampling pe-
riods reflecting the regenerative process are needed
Future research should focus on employing standardised
protocols for collecting, storing and analysing GCF markers
and establishing adequate statistical power to reach conclu-
sions that may shed light in the biological events involved in
the early periodontal wound healing and thus facilitate the
development of predictable regenerative treatments
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